Legal entity
AstraZeneca is most often covered alongside Brianne Dressen, which appears in 1 of these 3 stories. Source depth averages 2.7 original sources per story, versus 3.5 across the same-window beat baseline. Across a 143-day span, the pace is roughly 0.1 stories per week.
Last mentioned: Sep 8, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
AstraZeneca is most often covered alongside Brianne Dressen, which appears in 1 of these 3 stories. Source depth averages 2.7 original sources per story, versus 3.5 across the same-window beat baseline. Across a 143-day span, the pace is roughly 0.1 stories per week. At 7.3, the average consequence score sits above the same-window beat average of 6.4. Coverage clusters in corporate-law, which accounts for 1 of those 3, with the remainder spread across 2 other categories. AstraZeneca appears in 3 tracked Legal stories published from March 14, 2026 through August 3, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 1121 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AstraZeneca. Shared-story counts are live from our verified record — not editorial picks.
Tenth Circuit reverses and remands
A three-judge panel holds that the PREP Act immunizes all claims for loss, including breach of contract, but remands for the lower court to determine whether AstraZeneca waived immunity via the informed consent form.
Vulnerability Reported
Dan Neidle of Tax Policy Associates alerts Companies House to the 'back key' security flaw.
Service Suspension
Companies House takes the WebFiling service offline on Friday evening to investigate the issue.
Guidance Issued
Official guidance released advising users on how to handle missed filing deadlines due to the outage.
District court denies motion to dismiss
A federal district judge rules that Dressen's breach-of-contract claim may not be barred by the PREP Act's immunity, allowing the lawsuit to proceed.
Clinical trial participation and alleged injury
Brianne Dressen receives AstraZeneca's COVID-19 trial vaccine and later experiences debilitating symptoms. She signs an informed consent form stating the company would cover injury-related medical costs.
The proposed mega-merger would immediately trigger intense antitrust reviews in the US, EU, and UK, testing the limits of Trump-era competition enforcement in the pharmaceutical sector. Significant divestitures and political pushback are likely, with a real risk of deal collapse.
In a significant interpretation of the PREP Act, a Tenth Circuit panel held that the statute's immunity extends to contractual damages, rejecting a plaintiff's breach-of-contract theory. The court also remanded to consider whether AstraZeneca's informed consent form constituted a waiver of that immunity.
The UK’s Companies House has taken its WebFiling service offline following the discovery of a critical security flaw that allowed users to view and edit sensitive personal data of company directors. The vulnerability, which could be exploited simply by using a browser's back button, has raised significant concerns regarding corporate identity theft and the integrity of the UK's business register.
Source: Sam Hall (gb) · Sam Hall (gb)
AstraZeneca is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
